CD2 | Jotup

EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing

Retrieved on:

Wednesday, December 13, 2023

Immunotherapy, Tumor microenvironment, Immunology, Chemistry, CMC, Lead, Therapy, CD2, Society, Control, EVOLVE, Bristol Myers Squibb, ULBP2, SITC, Vaccine

BRANFORD, Conn., Dec. 13, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immune therapy agents, today provided a corporate and program update related to the advancement of its pipeline of first-in-category precision immuno-oncology agents. The company announced the closing of a $37 million financing round, which was supported by existing investors including Pfizer Ventures, Solasta Ventures, and Takeda Ventures, Inc., along with new strategic investor Bristol Myers Squibb.

Key Points:

The company announced the closing of a $37 million financing round, which was supported by existing investors including Pfizer Ventures, Solasta Ventures, and Takeda Ventures, Inc., along with new strategic investor Bristol Myers Squibb.
EvolveImmune intends to use the proceeds from this fundraising to support continued platform and pipeline development including the advancement of its lead multi-functional T-cell engager program, EV-104.
“This new capital raise comes at an exciting time for EvolveImmune,” said Stephen Bloch, M.D., chief executive officer of EvolveImmune.
The platform also takes advantage the company’s understanding of specific tumor cell characteristics to guide tumor antigen prioritization and program differentiation.

CARGO Therapeutics Announces Scientific Advisory Board

Retrieved on:

Wednesday, December 6, 2023

SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.

Key Points:

SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
The SAB will provide strategic counsel and critical expertise as CARGO advances its mission to develop the next generation of transformational CAR T-cell therapies.
“The SAB stands out by bringing together several highly accomplished translational investigators each with CAR T-cell experience that bridges both the laboratory and the clinic,” said Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair.
“They are uniquely suited to advise CARGO on their scientific goals and directions that will lead to better outcomes for patients.”
Members of the CARGO Scientific Advisory Board are listed below; full bios are available on the CARGO website .

EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on:

Monday, November 6, 2023

In addition, presented data highlighted the robust anti-tumor efficacy exhibited by lead molecules for the EV-104 and EV-106 programs in patient-derived solid tumor models.

Key Points:

In addition, presented data highlighted the robust anti-tumor efficacy exhibited by lead molecules for the EV-104 and EV-106 programs in patient-derived solid tumor models.
The EVOLVE platform uniquely unleashes potent, selective and integrated T cell costimulation, which amplifies and sustains the tumor killing capacity of these T cells.
The platform also takes advantage the company’s understanding of specific tumor cell characteristics to guide tumor antigen prioritization and program differentiation.
In a poster presentation at SITC, EvolveImmune spotlighted advances to the company’s first-in-class EV-104 program, a novel multi-functional T cell engager with integrated CD2 costimulation which conditionally targets ULBP2.

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

Retrieved on:

Tuesday, October 31, 2023

Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced an update regarding the company’s patent covering its proprietary cell line, “INB16”, as well as the therapeutic composition comprising replication-incompetent INB16 cells known as “INKmune™” and methods of treating cancer by administering INKmune™, with a goal of achieving in vivo priming of natural killer (NK) cells to enhance the ability of a patient’s own NK-cells to effect cancer surveillance, recognition, and killing.

Key Points:

INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition.
The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells (“INKmune™”) and methods of treating cancer in patients by administering INKmune™.
“Patents covering novel cell lines are somewhat rare in practice and form a very small number of total patents issued,” said Joshua Schoonover, Esq., in-house General Counsel for the Company.
INB16 is a tumor cell line which is relatively insensitive to killing by natural killer (NK) cells from healthy donors and from patients.

EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on:

Wednesday, October 18, 2023

EVOLVE, Regulation, Impact, Research, SITC, B7-H4, Immunotherapy, Yale Cancer Center, Tumor microenvironment, Immunology, Society, Cancer, Therapy, Patient, CD2, Neoplasm, Vaccine

BRANFORD, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immune therapy agents, today announced that new preclinical and translational data highlighting EVOLVE, the company’s novel costimulatory T cell engager platform, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 1-5, 2023, in San Diego, California. The poster presentations will unveil the company’s pioneering insights into the impact of tumor lineages on tumor antigen expression and immune infiltration in the tumor microenvironment. These features suggest the potential for patient-tailored immunotherapeutic strategies for EvolveImmune’s expanding pipeline of novel costimulatory T cell engagers.

Key Points:

These features suggest the potential for patient-tailored immunotherapeutic strategies for EvolveImmune’s expanding pipeline of novel costimulatory T cell engagers.
The EVOLVE platform uniquely unleashes potent, selective and integrated T cell costimulation, which amplifies and sustains the tumor killing capacity of these T cells.
In two poster presentations, EvolveImmune will highlight how the differentiated aspects of the EVOLVE platform are being applied to two solid tumor programs, EV-104 and EV-106.
By supplying this second costimulatory signal to T cells, their cancer killing capacity is both heightened and prolonged.

CD2 Learning Wins Top 15 All-Purpose Learning Systems Award for 2023

Retrieved on:

Tuesday, October 17, 2023

Learning, Education, Nelnet, Integrated learning systems, Organization, Research, Leh, SCORM, CD2, Tutoring, Management

LINCOLN, Neb., Oct. 17, 2023 /PRNewswire/ -- CD2 Learning , a Nelnet company and learning management platform and content management provider, was honored to be named in Talented Learning's Top 15 All-Purpose Learning Systems .

Key Points:

LINCOLN, Neb., Oct. 17, 2023 /PRNewswire/ -- CD2 Learning , a Nelnet company and learning management platform and content management provider, was honored to be named in Talented Learning's Top 15 All-Purpose Learning Systems .
Last year, CD2 Learning was listed in the Top 20 All-Purpose Learning System by Talented Learning.
"We are honored to celebrate this achievement with our customers and team," said Scott Spethman, president of CD2 Learning.
Working with organizations of all sizes, CD2 provides a learning management system platform and content creation services that help gamify personalized learning.

CD2 Learning and CampusGuard Partner to Empower Corporate Cybersecurity Training

Retrieved on:

Thursday, August 17, 2023

CD2, Habit, LMS, Tutoring

LINCOLN, Neb., Aug. 17, 2023 /PRNewswire/ -- CD2 Learning, a learning management system (LMS) platform and course creation team, is honored to partner with CampusGuard, LLC, a full-service cybersecurity and compliance services firm.

Key Points:

LINCOLN, Neb., Aug. 17, 2023 /PRNewswire/ -- CD2 Learning, a learning management system (LMS) platform and course creation team, is honored to partner with CampusGuard, LLC, a full-service cybersecurity and compliance services firm.
Building upon CampusGuard's comprehensive course library and content, CD2 provided instructional design to enhance the online training courses that CampusGuard delivers to its customers.
CampusGuard's enhanced training library will now be available within the top-rated CD2 Learning platform.
The CD2 Learning team helped make our employee awareness training offerings more interactive to increase user engagement and understanding."

CD2 Learning and Traliant Partner to Enhance Compliance Training's Impact

Retrieved on:

Tuesday, August 15, 2023

Organization, CD2, Ethics, Partnership, Health, LMS, E-commerce, Gold, Safety, Learning, Tutoring

LINCOLN, Neb., Aug. 15, 2023 /PRNewswire/ -- CD2 Learning, a learning management system (LMS) platform, and Traliant, an innovator in online compliance training, are announcing a partnership to streamline and simplify the compliance process for employees and human resources professionals.

Key Points:

LINCOLN, Neb., Aug. 15, 2023 /PRNewswire/ -- CD2 Learning, a learning management system (LMS) platform, and Traliant, an innovator in online compliance training, are announcing a partnership to streamline and simplify the compliance process for employees and human resources professionals.
"We're proud to partner with Traliant, who has a proven track record of excellence in interactive and memorable compliance training," said Jay Breeden, president of CD2 Learning.
Winner of the 2023 Gold Stevie Award in Customer Education LMS , CD2 Learning's corporate learning management system offers a content library, certification compliance tracking, social collaboration, reporting library, eCommerce storefront, personalized learning tracks and onboarding workflows.
In a world of constantly evolving laws, regulations and policies, CD2 Learning and Traliant are committed to alleviating the burden for human resources professionals.

CD2 Learning and iorad Partner to Deliver eLearning and Training Solutions

Retrieved on:

Thursday, July 13, 2023

Organization, Learning, CD2, Partnership, Nelnet, LMS, Science and technology in Asia, Tutoring

This collaboration brings together CD2 Learning's robust learning management system (LMS) and iorad's innovative tutorial building platform to deliver engaging eLearning solutions for organizations worldwide.

Key Points:

This collaboration brings together CD2 Learning's robust learning management system (LMS) and iorad's innovative tutorial building platform to deliver engaging eLearning solutions for organizations worldwide.
CD2 Learning offers a comprehensive learning management system that empowers businesses to create, manage and deliver engaging training content.
"We are thrilled to partner with iorad to redefine the way organizations approach digital learning and training," said Jay Breeden, president of CD2 Learning.
"We are excited to join forces with CD2 Learning to transform the digital learning landscape," said Sean Adams, head of partnerships at iorad.

EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology

Retrieved on:

Wednesday, June 14, 2023

CD2, Partnership, University, Immunology, CD3, Research, Kennedy Institute, CD8, Therapy, EVOLVE, SLB, Vaccine

Dr. Dustin is the Kennedy Trust Professor of Molecular Immunology and director of Research for the Kennedy Institute of Rheumatology at the University of Oxford.

Key Points:

Dr. Dustin is the Kennedy Trust Professor of Molecular Immunology and director of Research for the Kennedy Institute of Rheumatology at the University of Oxford.
This is achieved through finely tuned T cell receptor and CD2 costimulation optimized for CD8 T cell function.
Dustin is at the forefront of driving our understanding of the molecular circuitry responsible for mediating immunological synapse formation and T cell effector function.
This strategic collaboration will leverage his group’s cutting-edge technologies and know-how to interrogate the differentiated mode of action of EVOLVE compared to traditional CD3 bispecific molecules,” said Jay Fine, Ph.D., president of research and development at EvolveImmune.